# RNN 1st Gen Model Biogen Idec Inc. Biological products, except diagnostic

Stock predictor AI models:
61.54% successful of 65 deals
$ 269.73 Last close price
at 18-oct-2021


Model's trade recommendations -0.02% Return for period

-7.60% Annual return

$57.84B Market Cap

β 0.84  


Model (following trade recommendations)


Underlying stock

S&P 500

Return for period -0.02%
52wk return -8.81%
52wk Range
Sortino ratio -0.30
Sharpe ratio -0.27
Norm. RMSE 0.74%
Downside risk 19.39%
Volatility 0.00%
  • STRONG BUY Analysts consensus recommendation

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia, and a deep clinical pipeline ranging from Alzheimer's disease, lupus nephritis to neuropathic pain.

Industry sector: Medical

Sector classification: Biological products, except diagnostic

Deep Learning based analysis and prediction model for Biogen Idec Inc. (BIIB) stock is a 1st Generation Non-linear Autoregresive with exogenous variable(s) (NARX) model based on the Recurrent Neural Network architecture.

Model is in the production pipeline since Oct. 2, 2015.

Market data for BIIB model training are being downloaded from the Quandl premium datasets on a daily basis.
Risks related to the novel coronavirus disease 2019 (COVID-19) caused by the virus named “SARS-CoV-2” are accounted for in this model in the form of the historical data coincided with outbreaks and other global events in the past used to train ML prediction model for BIIB.

Model is being retrained on a daily basis.

Float 210M
P/E 12.10
Shares Outstanding 211M
% Held by Insiders 0.25%
% Held by Institutions 89.00%
EPS (last reported FY) $21.81
EPS (last reported Q) $6.05
EPS, estimated (last reported Q) $5.93
Total revenues $12 B
Net income $3 B